294 related articles for article (PubMed ID: 11495036)
1. Diabetic KKAy mice exhibit increased hepatic PPARgamma1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones.
Bedoucha M; Atzpodien E; Boelsterli UA
J Hepatol; 2001 Jul; 35(1):17-23. PubMed ID: 11495036
[TBL] [Abstract][Full Text] [Related]
2. Up-regulation of peroxisome proliferator-activated receptors (PPAR-alpha) and PPAR-gamma messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-gamma-responsive adipose tissue-specific genes in the liver of obese diabetic mice.
Memon RA; Tecott LH; Nonogaki K; Beigneux A; Moser AH; Grunfeld C; Feingold KR
Endocrinology; 2000 Nov; 141(11):4021-31. PubMed ID: 11089532
[TBL] [Abstract][Full Text] [Related]
3. A novel method for analysis of nuclear receptor function at natural promoters: peroxisome proliferator-activated receptor gamma agonist actions on aP2 gene expression detected using branched DNA messenger RNA quantitation.
Burris TP; Pelton PD; Zhou L; Osborne MC; Cryan E; Demarest KT
Mol Endocrinol; 1999 Mar; 13(3):410-7. PubMed ID: 10076998
[TBL] [Abstract][Full Text] [Related]
4. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones.
Chao L; Marcus-Samuels B; Mason MM; Moitra J; Vinson C; Arioglu E; Gavrilova O; Reitman ML
J Clin Invest; 2000 Nov; 106(10):1221-8. PubMed ID: 11086023
[TBL] [Abstract][Full Text] [Related]
5. Troglitazone effects on gene expression in human skeletal muscle of type II diabetes involve up-regulation of peroxisome proliferator-activated receptor-gamma.
Park KS; Ciaraldi TP; Lindgren K; Abrams-Carter L; Mudaliar S; Nikoulina SE; Tufari SR; Veerkamp JH; Vidal-Puig A; Henry RR
J Clin Endocrinol Metab; 1998 Aug; 83(8):2830-5. PubMed ID: 9709955
[TBL] [Abstract][Full Text] [Related]
6. Rosiglitazone (BRL49653), a PPARgamma-selective agonist, causes peroxisome proliferator-like liver effects in obese mice.
Edvardsson U; Bergström M; Alexandersson M; Bamberg K; Ljung B; Dahllöf B
J Lipid Res; 1999 Jul; 40(7):1177-84. PubMed ID: 10393202
[TBL] [Abstract][Full Text] [Related]
7. Hepatic over-expression of peroxisome proliferator activated receptor gamma2 in the ob/ob mouse model of non-insulin dependent diabetes mellitus.
Rahimian R; Masih-Khan E; Lo M; van Breemen C; McManus BM; Dubé GP
Mol Cell Biochem; 2001 Aug; 224(1-2):29-37. PubMed ID: 11693197
[TBL] [Abstract][Full Text] [Related]
8. Toxicological consequences of altered peroxisome proliferator-activated receptor gamma (PPARgamma) expression in the liver: insights from models of obesity and type 2 diabetes.
Boelsterli UA; Bedoucha M
Biochem Pharmacol; 2002 Jan; 63(1):1-10. PubMed ID: 11754868
[TBL] [Abstract][Full Text] [Related]
9. Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation.
Ellis CN; Varani J; Fisher GJ; Zeigler ME; Pershadsingh HA; Benson SC; Chi Y; Kurtz TW
Arch Dermatol; 2000 May; 136(5):609-16. PubMed ID: 10815854
[TBL] [Abstract][Full Text] [Related]
10. A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat.
Brown KK; Henke BR; Blanchard SG; Cobb JE; Mook R; Kaldor I; Kliewer SA; Lehmann JM; Lenhard JM; Harrington WW; Novak PJ; Faison W; Binz JG; Hashim MA; Oliver WO; Brown HR; Parks DJ; Plunket KD; Tong WQ; Menius JA; Adkison K; Noble SA; Willson TM
Diabetes; 1999 Jul; 48(7):1415-24. PubMed ID: 10389847
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation by troglitazone of hepatic tumor necrosis factor-alpha and interleukin-6 mRNA expression in a murine model of non-insulin-dependent diabetes.
Sigrist S; Bedoucha M; Boelsterli UA
Biochem Pharmacol; 2000 Jul; 60(1):67-75. PubMed ID: 10807946
[TBL] [Abstract][Full Text] [Related]
12. Unique ability of troglitazone to up-regulate peroxisome proliferator-activated receptor-gamma expression in hepatocytes.
Davies GF; McFie PJ; Khandelwal RL; Roesler WJ
J Pharmacol Exp Ther; 2002 Jan; 300(1):72-7. PubMed ID: 11752099
[TBL] [Abstract][Full Text] [Related]
13. Peroxisome proliferator-activated receptor gamma1 (PPARgamma1) expresses in rat mesangial cells and PPARgamma agonists modulate its differentiation.
Asano T; Wakisaka M; Yoshinari M; Iino K; Sonoki K; Iwase M; Fujishima M
Biochim Biophys Acta; 2000 Jun; 1497(1):148-54. PubMed ID: 10838168
[TBL] [Abstract][Full Text] [Related]
14. Troglitazone prevents fatty changes of the liver in obese diabetic rats.
Jia DM; Tabaru A; Akiyama T; Abe S; Otsuki M
J Gastroenterol Hepatol; 2000 Oct; 15(10):1183-91. PubMed ID: 11106100
[TBL] [Abstract][Full Text] [Related]
15. How should patients taking the discontinued diabetes drug troglitazone be managed?
Reddy SS
Cleve Clin J Med; 2000 Jun; 67(6):401-2, 455. PubMed ID: 10860221
[No Abstract] [Full Text] [Related]
16. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass.
Gavrilova O; Haluzik M; Matsusue K; Cutson JJ; Johnson L; Dietz KR; Nicol CJ; Vinson C; Gonzalez FJ; Reitman ML
J Biol Chem; 2003 Sep; 278(36):34268-76. PubMed ID: 12805374
[TBL] [Abstract][Full Text] [Related]
17. The orphan nuclear receptor small heterodimer partner is required for thiazolidinedione effects in leptin-deficient mice.
Tseng HT; Park YJ; Lee YK; Moore DD
J Biomed Sci; 2015 May; 22(1):30. PubMed ID: 25951943
[TBL] [Abstract][Full Text] [Related]
18. Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone.
Camp HS; Li O; Wise SC; Hong YH; Frankowski CL; Shen X; Vanbogelen R; Leff T
Diabetes; 2000 Apr; 49(4):539-47. PubMed ID: 10871190
[TBL] [Abstract][Full Text] [Related]
19. A new thiazolidinedione, NC-2100, which is a weak PPAR-gamma activator, exhibits potent antidiabetic effects and induces uncoupling protein 1 in white adipose tissue of KKAy obese mice.
Fukui Y; Masui S; Osada S; Umesono K; Motojima K
Diabetes; 2000 May; 49(5):759-67. PubMed ID: 10905484
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of YM440 a hypoglycemic agent on binding to a peroxisome proliferator-activated receptor gamma and its transactivation.
Kurosaki E; Nakano R; Shimaya A; Yoshida S; Ida M; Suzuki T; Shibasaki M; Shikama H
Biochem Pharmacol; 2003 Mar; 65(5):795-805. PubMed ID: 12628477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
